Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q4 2022 Earnings Call Transcript

As it facilitates discussion of the evidence at a treatment group level. And we know this is an industry best practice and I know perhaps is confusing from the questions you’re asking. But fundamentally, when we look back to the forefront and even the diverse in ADCOM from very recently, there were important scientific benefits from preserving the confidentiality of treatment assignments as they did as well in the interpretation of future data as it reduces bias in the open label period of their study. These same parallels exist for us with the Expanded Access program, so I hope this gives you some insight, we are absolutely motivated by what is best and would be in the best interest of the entire set of people living with ALS, who could benefit from an approval and that is at the forefront of our actions.

Unidentified Analyst: Okay. Thank you. And I appreciate your explanation. Thank you.

Stacy Lindborg: Thank you.

Chaim Lebovits: Holly?

Operator: We have reached the end of our question-and-answer session. And I will now turn the call over to management for any closing remarks.

Chaim Lebovits: No, just thank you very much. Thanks, holly very well done this call. Thanks everyone for all the questions and have a nice day.

Operator: This concludes today’s conference and you may disconnect your lines at this time. Thank you for your participation.